Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 4.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 3.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nurix Therapeutics was 13.40% per year. The lowest was -83.90% per year. And the median was -4.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Nurix Therapeutics 5-Year EBITDA Growth Rate Related Terms
NRIX vs ATAI, SLS, VRDN: 5-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Nurix Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics 5-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 3.60% mean?
Nurix Therapeutics (NRIX) has a 5-Year EBITDA Growth Rate of 3.60% as of May. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Nurix Therapeutics and its competitors.
Is Nurix Therapeutics' 5-Year EBITDA Growth Rate too high?
Nurix Therapeutics' current 5-Year EBITDA Growth Rate is 3.60%. Overall, Nurix Therapeutics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nurix Therapeutics' 5-Year EBITDA Growth Rate compare to ATAI and SLS?
Nurix Therapeutics' 5-Year EBITDA Growth Rate of 3.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Nurix Therapeutics and its competitors. Nurix Therapeutics's current 5-Year EBITDA Growth Rate is 3.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nurix Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nurix Therapeutics (NRIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.58, compared to a current price of $26.13 — trading 244.7% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 3.60%. Nurix Therapeutics' overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Nurix Therapeutics (NRIX), the current 5-Year EBITDA Growth Rate is 3.60% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nurix Therapeutics (NRIX) Overvalued in 2026?
Based on GuruFocus' analysis, Nurix Therapeutics stock appears to be overvalued.
The current stock price of $26.13 is trading 244.7% above its estimated GF Value™ of $7.58.
GuruFocus considers Nurix Therapeutics to be Significantly Overvalued.
Key valuation signals for NRIX:
5-Year EBITDA Growth Rate: 3.60%
GF Value™: $7.58 vs. price of $26.13 (244.7% above fair value)
No single metric tells the full story. See the NRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
59GF Score
Get the complete analysis for NRIX
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRIX has been successfully added to your 
